What if I have secondary HPT?

If you have secondary HPT, there are some things you can do to help manage the disease:

Keep your lab values balanced
If you have secondary HPT, it is important to keep three lab values balanced—PTH, Calcium and Phosphorus. If these lab values do not stay where they need to be, you may be at risk for bone disease and other problems.¹ Learn more about how you can keep your lab values balanced.

Learn which medicines can help you keep your lab values balanced
There are many medicines your doctor may prescribe to help keep your lab values balanced. Learn more about which medicines you may take to help balance your lab values and control secondary HPT.

Eat a healthy diet
If you are on dialysis, it is important to watch the phosphorus in your foods. Work with your dietician and health care team to find the right diet for you.

Sensipar^® is indicated for the treatment of secondary hyperparathyroidism (HPT) in patients with chronic kidney disease (CKD) on dialysis.

Important Safety Information

Sensipar^® treatment should not be started if you have low calcium levels. Ask your doctor about the normal ranges.
Before starting Sensipar^®, tell your doctor if you are taking medication to prevent seizures or have had seizures in the past. Report any seizure episodes while on Sensipar^® therapy.
Very infrequent cases of low blood pressure, worsening heart failure, and/or abnormal heart rhythm (arrhythmia) have been reported in patients with impaired heart function taking Sensipar^®.
While on Sensipar^®, your doctor should perform repeated blood tests to monitor calcium, phosphorus, and intact parathyroid hormone (iPTH) levels. Very low and very high levels of PTH should be avoided to help maintain bone health. Very low levels (iPTH < 100 pg/mL) of PTH may cause a condition your doctor may refer to as adynamic bone disease.
Patients with moderate to severe liver impairment should be monitored throughout treatment with Sensipar^®.
Tell your doctor if you experience any muscle spasms, aches or cramping, tingling in your limbs, or seizures.
In clinical trials, the most common side effects reported in patients were nausea, vomiting, and diarrhea. If you have any questions about this information, be sure to discuss them with your doctor.

Reference

National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42(suppl 3):S1-S201.

This site is intended for a US audience only.

Prescribing Information | Important Safety Information | General Conformity Certificates
Terms of Use | Privacy Statement